Your browser doesn't support javascript.
loading
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release.
Schardt, John S; Walseng, Even; Le, Kim; Yang, Chunning; Shah, Pooja; Fu, Ying; Alam, Kausar; Kelton, Cathryn R; Gu, Yu; Huang, Fengying; Lin, Jia; Liu, Wenhai; Dippel, Andrew; Zhang, Hanzhi; Mulgrew, Kathy; Pryts, Stacy; Chennupati, Vijaykumar; Chen, Hung-Chang; Denham, Jessica; Chen, Xiaoru; Pradhan, Pallab; Wu, Yuling; Hardman, Colin; Zhao, Chihao; Kierny, Michael; Song, Yang; Dovedi, Simon J; Cemerski, Saso; Mazor, Yariv.
Affiliation
  • Schardt JS; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Walseng E; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Le K; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Yang C; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Shah P; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Fu Y; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Alam K; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Kelton CR; Oncology ICC, AstraZeneca, Gaithersburg, MD, USA.
  • Gu Y; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Huang F; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Lin J; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Liu W; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Dippel A; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Zhang H; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Mulgrew K; Oncology ICC, AstraZeneca, Gaithersburg, MD, USA.
  • Pryts S; Oncology ICC, AstraZeneca, Gaithersburg, MD, USA.
  • Chennupati V; Data Science and Advanced Analytics, AstraZeneca, Gaithersburg, MD, USA.
  • Chen HC; Data Science and Advanced Analytics, AstraZeneca, Gaithersburg, MD, USA.
  • Denham J; Oncology ICC, AstraZeneca, Cambridge, UK.
  • Chen X; Oncology ICC, AstraZeneca, Cambridge, UK.
  • Pradhan P; Oncology ICC, AstraZeneca, Cambridge, UK.
  • Wu Y; Oncology ICC, AstraZeneca, Cambridge, UK.
  • Hardman C; Discovery Bioanalysis, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Zhao C; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Kierny M; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Song Y; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
  • Dovedi SJ; Data Science and Advanced Analytics, AstraZeneca, Gaithersburg, MD, USA.
  • Cemerski S; Oncology ICC, AstraZeneca, Gaithersburg, MD, USA.
  • Mazor Y; R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA.
MAbs ; 16(1): 2395499, 2024.
Article in En | MEDLINE | ID: mdl-39205483
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interleukin-2 / Antibodies, Bispecific / CD8-Positive T-Lymphocytes Limits: Animals / Humans Language: En Journal: MAbs Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interleukin-2 / Antibodies, Bispecific / CD8-Positive T-Lymphocytes Limits: Animals / Humans Language: En Journal: MAbs Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos